Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

Farshad Nassiri^{1

2}, Vikas Patil², Leeor S Yefet², Olivia Singh², Jeff Liu², Rachel M A Dang³, Takafumi N Yamaguchi³, Mariza Daras⁴, Timothy F Cloughesy⁵, Howard Colman⁶, Priya U Kumthekar⁷, Clark C Chen⁸, Robert Aiken⁹, Morris D Groves¹⁰, Shirley S Ong¹¹, Rohan Ramakrishna¹², Michael A Vogelbaum¹³, Simon Khagi¹⁴, Thomas Kaley¹⁵, Jason M Melear¹⁶, David M Peereboom¹⁷, Analiz Rodriguez¹⁸, Maxim Yankelevich¹⁹, Suresh G Nair²⁰, Vinay K Puduvalli²¹, Kenneth Aldape²², Andrew Gao²³, Álvaro López-Janeiro^{24

25}, Carlos E de Andrea^{24

25}, Marta M Alonso^{25

26

27}, Paul Boutros³, Joan Robbins²⁸, Warren P Mason², Adam M Sonabend^{29

30}, Roger Stupp^{29

30

31

32}, Juan Fueyo²¹, Candelaria Gomez-Manzano²¹, Frederick F Lang³³, Gelareh Zadeh^{34

35

36}

Affiliations

¹ Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada.
² Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
³ Department of Human Genetics, University of California Los Angeles, Los Angeles, CA, USA.
⁴ Division of Neuro-oncology, University of California San Francisco, San Francisco, CA, USA.
⁵ UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
⁶ Huntsman Cancer Institute and Department of Neurosurgery, University of Utah, Salt Lake City, UT, USA.
⁷ Department of Neurology, Division of Neuro-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
⁸ Department of Neurosurgery, University of Minnesota, Minneapolis, MI, USA.
⁹ Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, USA.
¹⁰ Department of Neurology, Texas Oncology, Austin, TX, USA.
¹¹ Division of Neuro-Oncology, Department of Neurology, the Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
¹² Department of Neurological Surgery, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA.
¹³ Department of Neuro-Oncology, Neuro-Oncology Program, Moffitt Cancer Center, Tampa, FL, USA.
¹⁴ Division of Medical Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
¹⁵ Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁶ Department of Internal Medicine, Baylor University Medical Center, Dallas, TX, USA.
¹⁷ The Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA.
¹⁸ Department of Neurosurgery, University of Arkansas for Medical Sciences, Little Rock, AK, USA.
¹⁹ Department of Pediatrics, University of Michigan, Ann Arbor Beaumont Children's Hospital, Royal Oak, MI, USA.
²⁰ Lehigh Valley Topper Cancer Institute, Allentown, PA, USA.
²¹ Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
²² Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA.
²³ Department of Laboratory Medicine and Pathobiology, University Health Network, Toronto, Ontario, Canada.
²⁴ Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.
²⁵ Navarra Institute for Health Research (IdISNA), Pamplona, Spain.
²⁶ Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.
²⁷ Program of Solid Tumors, Center for the Applied Medical Research (CIMA), Pamplona, Spain.
²⁸ DNATrix Inc., Carlsbad, CA, USA.
²⁹ Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
³⁰ Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
³¹ Department of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
³² Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
³³ Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³⁴ Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada. gelareh.zadeh@uhn.ca.
³⁵ Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada. gelareh.zadeh@uhn.ca.
³⁶ Department of Surgery, University of Toronto, Toronto, Ontario, Canada. gelareh.zadeh@uhn.ca.

PMID: 40691367
PMCID: PMC12443589
DOI: 10.1038/s41591-025-03895-1

Published Erratum

Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

Farshad Nassiri et al. Nat Med. 2025 Sep.

. 2025 Sep;31(9):3204.

doi: 10.1038/s41591-025-03895-1.

Authors

Affiliations

¹ Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada.
² Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
³ Department of Human Genetics, University of California Los Angeles, Los Angeles, CA, USA.
⁴ Division of Neuro-oncology, University of California San Francisco, San Francisco, CA, USA.
⁵ UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
⁶ Huntsman Cancer Institute and Department of Neurosurgery, University of Utah, Salt Lake City, UT, USA.
⁷ Department of Neurology, Division of Neuro-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
⁸ Department of Neurosurgery, University of Minnesota, Minneapolis, MI, USA.
⁹ Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, USA.
¹⁰ Department of Neurology, Texas Oncology, Austin, TX, USA.
¹¹ Division of Neuro-Oncology, Department of Neurology, the Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
¹² Department of Neurological Surgery, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA.
¹³ Department of Neuro-Oncology, Neuro-Oncology Program, Moffitt Cancer Center, Tampa, FL, USA.
¹⁴ Division of Medical Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
¹⁵ Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁶ Department of Internal Medicine, Baylor University Medical Center, Dallas, TX, USA.
¹⁷ The Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA.
¹⁸ Department of Neurosurgery, University of Arkansas for Medical Sciences, Little Rock, AK, USA.
¹⁹ Department of Pediatrics, University of Michigan, Ann Arbor Beaumont Children's Hospital, Royal Oak, MI, USA.
²⁰ Lehigh Valley Topper Cancer Institute, Allentown, PA, USA.
²¹ Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
²² Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA.
²³ Department of Laboratory Medicine and Pathobiology, University Health Network, Toronto, Ontario, Canada.
²⁴ Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.
²⁵ Navarra Institute for Health Research (IdISNA), Pamplona, Spain.
²⁶ Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.
²⁷ Program of Solid Tumors, Center for the Applied Medical Research (CIMA), Pamplona, Spain.
²⁸ DNATrix Inc., Carlsbad, CA, USA.
²⁹ Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
³⁰ Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
³¹ Department of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
³² Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
³³ Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³⁴ Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada. gelareh.zadeh@uhn.ca.
³⁵ Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada. gelareh.zadeh@uhn.ca.
³⁶ Department of Surgery, University of Toronto, Toronto, Ontario, Canada. gelareh.zadeh@uhn.ca.

PMID: 40691367
PMCID: PMC12443589
DOI: 10.1038/s41591-025-03895-1

No abstract available

PubMed Disclaimer

Erratum for

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, López-Janeiro Á, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh G. Nassiri F, et al. Nat Med. 2023 Jun;29(6):1370-1378. doi: 10.1038/s41591-023-02347-y. Epub 2023 May 15. Nat Med. 2023. PMID: 37188783 Free PMC article. Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

Affiliations

Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources